Washington Post Publisher Will Lewis Steps Down After Layoffs 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SOUTH PLAINFIELD, N.J. and CHARLOTTE, N.C., Nov. 09, 2016 -- Molecular diagnostics company, Admera Health announced the official launch of OncoGxSelect™ while exhibiting at the Association for Molecular Pathology (AMP) 2016 Annual Meeting in Charlotte, North Carolina. OncoGxSelect™ is a Next Generation Sequencing (NGS)-based test for tumor profiling of common cancer types, assaying 12 genes for mutations that align with well-established national guidelines for molecular testing and therapeutic decision making. The panel genes are: ALK, BRAF, EGFR, ERBB2, KIT, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET and ROS1. Mutations in these genes are frequently the underlying driver of non-small cell lung cancer (NSCLC), melanoma, thyroid, gastrointestinal and breast cancers. Results from OncoGxSelect™ provide targeted therapy recommendations based on gene mutation and tumor type. In addition, relevant, recruiting clinical trials are reported.
OncoGxSelect™ expands Admera’s Oncology Test Portfolio, which also includes OncoGxOne™, a comprehensive 64-gene tumor profiling panel, and PGxOne™ Plus, a pharmacogenomics panel that provides recommendations for over 220 commercial drugs, including cancer, anti-emetic and pain management drugs.
Guanghui Hu, PhD, President and CEO of Admera Health, commented, “The OncoGxSelect™ panel detects clinically actionable mutations that are associated with targeted therapies.” Hu went on to elaborate, “Although Admera already offered comprehensive tumor profiling, with this product launch we can now provide oncologists with a focused panel that follows well-accepted national clinical guidelines.”
Admera Health is exhibiting in Booth #2312 at the AMP 2016 Annual Meeting this week on November 10, 11 and 12.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
